<scp>GRAP2</scp> is a prognostic biomarker and correlated with immune infiltration in lung adenocarcinoma

Song, Shimao; Deng, Xinzhou; Jiang, Shan; Tian, Chao; Han, Jiahui; Chai, Jing; Li, Na; Yan, Yutao; Luo, Zhiguo

doi:10.1002/jcla.24662

Cited by 7 publications

(5 citation statements)

References 42 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that GRAP2 may be used as a new prognostic biomarker to guide clinical treatment strategies. Similar findings were confirmed in another study [19], wherein GRAP2 was shown to predict survival status in lung adenocarcinoma patients. Furthermore, it has been claimed that GRAP2 is linked to metastasis in cervical cancer.…”

Section: Discussionsupporting

confidence: 85%

“…The latest research suggests that GADS is recruited to phosphorylated CD28 to activate T cells [18]. Increasing evidence has demonstrated that GRAP2 seems to serve as a protective factor in lung cancer [19]. Furthermore, in this study, we outlined the relationship between GRAP2 expression and clinical information in the TCGA-CESC database (Table 1) and observed that GRAP2 expression is closely associated with survival time and M stage in cervical cancer patients.…”

Section: Grap2 Expression Was Related To Survival and Clinicopatholog...mentioning

confidence: 73%

See 1 more Smart Citation

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

Lin¹,

Zhu²,

Mao³

et al. 2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Immune infiltration of the tumor microenvironment offers unlimited possibilities for therapeutic strategies in cervical cancer, where GRAP2 is an adaptor protein engaged in diverse signal activations. However, uncertainty exists regarding GRAP2's prognostic significance and its relationship to immune infiltration. Methods: The data on cervical cancer cases were downloaded from The Cancer Genome Atlas (TCGA) database. The ESTIMATE computational technique was utilized to calculate the amount of immunological and stromal components, which helped us to identify the differential expression genes (DEGs). Among them, GRAP2 was considered to be related to overall survival based on a protein-protein interaction network and a univariate Cox regression analysis. Thus, based on the Gene Expression Omnibus (GEO) and TCGA databases, we evaluated GRAP2's influence on clinical prognosis. Furthermore, GRAP2 expression was analyzed by Gene Set Enrichment Analysis (GSEA). Finally, we used CIBERSORTx analysis to assess the proportion of tumor-infiltrating immune cells (TICs) and the connection between GRAP2 and the tumor immune microenvironment. Results: ES-TIMATEScore was associated with cervical cancer patient's prognosis. There are 791 DEGs and 11 potential key genes were identified including GRAP2. In survival analyses with clinical information, We found that the GRAP2 high expression group exhibited a significantly longer overall survival (OS) than the low expression group and that the gene expression gradually declined as the Federation of International of Gynecologists and Obstetricians (FIGO) stage and M classification increased. GRAP2 was strongly linked with immunity and metabolism, according to GSEA. Finally, we discovered that 11 different TIC types and GRAP2 expressions were linked. Conclusions: GRAP2 may be a novel immune-related prognosis biomarker in cervical cancer.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Grap2 Expression Was Related To Survival and Clinicopatholog...mentioning

confidence: 73%

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

Lin¹,

Zhu²,

Mao³

et al. 2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

show abstract

“…In addition, some chemokines can directly enhance the activity of immune cells ( Glodde and Hölzel, 2017 ). In the immunotherapy of glioma, the application of exogenous chemokines can significantly increase the infiltration of immune cells at the tumor site and enhance the antitumor immune response ( Song et al, 2022 ). In conclusion, chemokines are important links that connect and amplify the systemic and local immune systems of the body, which is an effective method to optimize the immunotherapy of glioma.…”

Section: Discussionmentioning

confidence: 99%

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis

Zhang,

Chen,

Jiang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Cytokines modulate the glioma tumor microenvironment, influencing occurrence, progression, and treatment response. Strategic cytokine application may improve glioma immunotherapy outcomes. Gliomas remain refractory to standard therapeutic modalities, but immunotherapy shows promise given the integral immunomodulatory roles of cytokines. However, systematic evaluation of cytokine glioma immunotherapy research is absent. Bibliometric mapping of the research landscape, recognition of impactful contributions, and elucidation of evolutive trajectories and hot topics has yet to occur, potentially guiding future efforts. Here, we analyzed the structure, evolution, trends, and hotspots of the cytokine glioma immunotherapy research field, subsequently focusing on avenues for future investigation.Methods: This investigation conducted comprehensive bibliometric analyses on a corpus of 1529 English-language publications, from 1 January 2000, to 4 October 2023, extracted from the Web of Science database. The study employed tools including Microsoft Excel, Origin, VOSviewer, CiteSpace, and the Bibliometrix R package, to systematically assess trends in publication, contributions from various countries, institutions, authors, and journals, as well as to examine literature co-citation and keyword distributions within the domain of cytokines for glioma immunotherapy. The application of these methodologies facilitated a detailed exploration of the hotspots, the underlying knowledge structure, and the developments in the field of cytokines for glioma immunotherapy.Results: This bibliometric analysis revealed an exponential growth in annual publications, with the United States, China, and Germany as top contributors. Reviews constituted 17% and research articles 83% of total publications. Analysis of keywords like “interleukin-13,” “TGF-beta,” and “dendritic cells” indicated progression from foundational cytokine therapies to sophisticated understanding of the tumor microenvironment and immune dynamics. Key research avenues encompassed the tumor microenvironment, epidermal growth factor receptor, clinical trials, and interleukin pathways. This comprehensive quantitative mapping of the glioma immunotherapy cytokine literature provides valuable insights to advance future research and therapeutic development.Conclusion: This study has identified remaining knowledge gaps regarding the role of cytokines in glioma immunotherapy. Future research will likely focus on the tumor microenvironment, cancer vaccines, epidermal growth factor receptor, and interleukin-13 receptor alpha 2. Glioma immunotherapy development will continue through investigations into resistance mechanisms, microglia and macrophage biology, and interactions within the complex tumor microenvironment.

show abstract

“…In this study, we used the kmplot database ( http://kmplot.Thecom/analysis/ ) ( 19 ) and GEPIA databases to perform the OS and DFS analysis. These two databases are public databases that are often used to analyze gene expression levels as well as survival time of patients ( 20 ).…”

Section: Methodsmentioning

confidence: 99%

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Jiang,

Deng,

Luo

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Background2’,5’-oligoadenylate synthetase 1 (OAS1), has been reported as a tumor driver gene in breast carcinoma and pancreatic carcinoma. However, the role of OAS1 in most tumors has not been reported.MethodsThe original data of 35 tumor types were down load from the TCGA (The Cancer Genome Atlas) database and Human Protein Atlas (HPA) database. TIMER2, Kmplot, UALCAN, and TISIDB tools were used to investigate the expression and function of OAS1, and the role of OAS1 in prognosis, diagnostic value, and immune characteristics of pan-cancer. LUAD and PRAD cell lines, A549, H1975, PC-3 and C4-2 were utilized to perform cell function tests.ResultsOAS1 expression was up-regulated in 12 tumor types and down-regulated in 2 tumor types. High OAS1 expression was correlated with poor prognosis in 6 tumor types, while high OAS1 expression was correlated with good prognosis in 2 tumor types. OAS1 was correlated with molecular subtypes in 8 tumor types and immune subtypes in 12 tumor types. OAS1 was positively associated with the expression of numerous immune checkpoint genes and tumor mutational burden (TMB). OAS1 had potential diagnostic value in 15 tumor types. Silence of OAS1 significantly inhibited the cell proliferation ability, and promoted G2/M cell cycle arrest of LUAD and PRAD cells. Meanwhile, silence of OAS1 enhanced cisplatin-induced apoptosis of LUAD and PRAD cells, but weakened cell migration.ConclusionThis pan-cancer study suggests that OAS1can be used as a molecular biomarker for prognosis in pan-cancer and may play an important role in tumor immune response.

show abstract

GRAP2 is a prognostic biomarker and correlated with immune infiltration in lung adenocarcinoma

Cited by 7 publications

References 42 publications

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

GRAP2: A Novel Immune-Related Prognosis Biomarker in Cervical Cancer

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Contact Info

Product

Resources

About